Is infection with hypermutable Pseudomonas aeruginosa clinically significant?

Journal of Cystic Fibrosis

Volumn 14, Issue 3, 2015, Pages 347-352

  Auerbach, Adi ^a   Kerem, Eitan ^b,c   Assous, Marc Victor ^a   Picard, Elie ^a,c   Bar Meir, Maskit ^a,c  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Cystic fibrosis; Hypermutable; Pseudomonas aeruginosa

Indexed keywords

COLISTIN; RIFAMPICIN; BACTERIAL DNA;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM COLONY; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; HYPERMUTABLE PSEUDOMONAS AERUGINOSA; INFANT; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; MULTIDRUG RESISTANCE; MUTATION RATE; NONHUMAN; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SCREENING TEST; STAPHYLOCOCCUS AUREUS; CHRONIC DISEASE; CLINICAL TRIAL; COMPLICATION; FOLLOW UP; GENETICS; ISOLATION AND PURIFICATION; LUNG; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; MUTATION; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; SPUTUM; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CYSTIC FIBROSIS; DNA MUTATIONAL ANALYSIS; DNA, BACTERIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; LUNG; MALE; MIDDLE AGED; MUTATION; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM; YOUNG ADULT;

EID: 84937392708     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.09.011     Document Type: Article

References (21)

1. Nixon G.M., Armstrong D.S., Carzino R., Carlin J.B., Olinsky A., Robertson C.F., et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr May 2001, 138(5):699-704.
2. Winnie G.B., Cowan R.G. Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti-Pseudomonas aeruginosa antibody levels and pulmonary function. Pediatr Pulmonol 1991, 10(2):92-100.
3. Kerem E., Viviani L., Zolin A., MacNeill S., Hatziagorou E., Ellemunter H., et al. ECFS Patient Registry Steering Group. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS Patient Registry. Eur Respir J Jan 2014, 43(1):125-133.
4. Henry R.L., Mellis C.M., Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol Mar 1992, 12(3):158-161.
5. Parad R.B., Gerard C.J., Zurakowski D., Nichols D.P., Pier G.B. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun Sep 1999, 67(9). [4744-X].
6. Oliver A., Canton R., Campo P., Baquero F., Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science May 19 2000, 288(5469):1251-1254.
7. Miller J.H. Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair. Annu Rev Microbiol 1996, 50:625-643.
8. Oliver A., Baquero F., Blazquez J. The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants. Mol Microbiol Mar 2002, 43(6):1641-1650.
9. Hogardt M., Hoboth C., Schmoldt S., Henke C., Bader L., Heesemann J. Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis. J Infect Dis Jan 1 2007, 195(1):70-80.
10. Oliver A., Levin B.R., Juan C., Baquero F., Blazquez J. Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob Agents Chemother Nov 2004, 48(11):4226-4233.
11. Smith A.L., Fiel S.B., Mayer-Hamblett N., Ramsey B., Burns J.L. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest May 2003, 123(5):1495-1502.
12. Lee T.W., Brownlee K.G., Conway S.P., Denton M., Littlewood J.M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros Mar 2003, 2(1):29-34.
13. Pressler T., Bohmova C., Conway S., Dumcius S., Hjelte L., Høiby N., et al. Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J Cyst Fibros Jun 2011, 10(Suppl. 2):S75-S78.
14. Manual of clinical microbiology 2003, ASM Press, Washington D.C. 8th ed. P.R. Murray, E.J. Baron, J.H. Jorgensen, M.A. Pfaller, R.H. Yolken (Eds.).
15. NCCLS Abbreviated identification of bacteria and yeast: approved guideline. M35-A 2002, NCCLS, Wayne, PA.
16. Magiorakos A.P., Srinivasan A., Carey R.B., Carmeli Y., Falagas M.F., Giske C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect Mar 2012, 18(3):268-281.
17. Maciá M.D., Borrell N., Pérez J.L., Oliver A. Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion. Antimicrob Agents Chemother Jul 2004, 48(7):2665-2672.
18. Waine D.J., Honeybourne D., Smith E.G., Whitehouse J.L., Dowson C.G. Association between hypermutator phenotype, clinical variables, mucoid phenotype, and antimicrobial resistance in Pseudomonas aeruginosa. J Clin Microbiol Oct 2008, 46(10):3491-3493.
19. Ferroni A., Guillemot D., Moumile K., Bernede C., Le Bourgeois M., Waernessyckle S., et al. Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis. Pediatr Pulmonol Aug 2009, 44(8):820-825.
20. Maciá M.D., Blanquer D., Togores B., Sauleda J., Pérez J.L., Oliver A. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother Aug 2005, 49(8):3382.
21. Maciá M.D., Mena A., Borrell N., Pérez J.L., Oliver A. Increased susceptibility to colistin in hypermutable Pseudomonas aeruginosa strains from chronic respiratory infections. Antimicrob Agents Chemother Dec 2007, 51(12):4531-4532.